Malignant Uterine Neoplasm — Trials

Malignant Uterine Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

3,291 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 824
Recruiting: 456
Ph III recruiting: 55
Growth YoY: −3.6%
Industry share: 24%
Top sponsor: National Cancer Institute (NCI)
Termination share: 25.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (333)

clinicaltrialsPublishedShowing 901–950 of 962 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00006224	Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix	terminated	Phase 2	—	Gynecologic Oncology GroupNETWORK	2	Apr 11, 2013	clinicaltrials
NCT00006482	Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix	terminated	Phase 2	—	Gynecologic Oncology GroupNETWORK	2	Apr 11, 2013	clinicaltrials